Cosmetic Product Safety for Oily/Acne-Prone Skin
Official title: Clinical Evaluation of Dermal and Ophthalmological Acceptability and Comedogenic and Acnegenic Potential of a Cosmetic Product
Run by Brainfarma Industria Química e Farmacêutica S/A · NCT07848555 · Data updated 2026-11-12
This study tests a cosmetic product to see if it is safe for oily or acne-prone skin and eye comfort when used on the face and body for 28 days.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 33 (estimated) |
| Sponsor | Brainfarma Industria Química e Farmacêutica S/A Industry-sponsored |
| Locations | 1 site (Osasco, São Paulo) |
| Status | Recruiting |
| Started | September 8, 2026 |
| Main results expected | October 28, 2026 |
| Study ends | October 28, 2026 |
| Registry record updated | September 30, 2026 |
| Trial ID | NCT07848555 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–45 with oily or acne-prone skin who consent to all procedures and attend scheduled visits.
✕Probably not a fit
Individuals with non-oily or non-acne-prone skin, or those with conditions that could confound evaluations, may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study evaluates the dermatological and ophthalmological safety, as well as the comedogenic and acnegenic potential of an investigational moisturizing cream. Participants with oily or acne-prone skin will apply the product to the face and body twice daily for 28 days and undergo regular skin and eye assessments. The study aims to determine whether the product remains non-irritating, non-comedogenic, and acceptable to participants under normal use conditions. Dermatology evaluations will monitor tolerability and adverse skin reactions, while ophthalmology evaluations will assess ocular tolerability. The trial is conducted at Grupo Medcin in Osasco, São Paulo, with Brainfarma as the lead sponsor.
Why it matters
Potential benefit: If successful, participants may experience safe use of a moisturizing cream with low risk of skin irritation and eye discomfort.
How similar studies have gone: Previous assessments of similar cosmetic products have shown variable tolerability; this study adds targeted dermatological and ophthalmological safety data for this formulation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female participants aged 18 to 45 years. * Participants with oily, acne-prone skin. * Willingness to comply with all study procedures and attend the study site on the scheduled dates and times for assessments. * Ability to understand the study requirements, provide written informed consent, and sign the Informed Consent Form (ICF). * Normal ophthalmological examination, including slit-lamp evaluation. Exclusion Criteria: * Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study, when applicable. * Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening. * Skin conditions or marks in the test area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn. * History of atopy or allergic reactions to cosmetic products. * Active skin diseases and/or lesions (localized or widespread) in the assessment area. * Immunosuppression due to medication use or active disease. * Uncontrolled endocrine disorders. * Relevant medical history or current evidence of alcohol or substance abuse. * Known history of or suspected intolerance to products of the same category. * Intense sun exposure within 15 days prior to assessment. * Aesthetic or dermatological treatments within 4 weeks prior to assessment. * Any other condition that, in the investigator's opinion, may reasonably justify exclusion from the study. Additional Ophthalmological Exclusion Criteria: * Presence of entropion, ectropion, hordeolum, conjunctivitis, uveitis, or other active ocular diseases at the time of screening. * Presence of corneal ulceration, blepharitis, meibomian gland dysfunction (meibomitis), pterygium, trichiasis, distichiasis, or other moderate to severe ocular conditions. * Initiation of contact lens use within 1 week prior to screening. * Use of ophthalmic products, including eye drops and/or ophthalmic ointments, within 3 weeks prior to screening. * Any other condition that, in the investigator's opinion, may reasonably justify exclusion from the study.
Where it's running
-
Grupo Medcin
Osasco, São Paulo, Brazil Recruiting
Study contacts
- Study coordinator: Layane Melody Da Silva Reis Cavalcante
- Email: layane.reis@brainfarma.ind.br
- Phone: +55 (11) 4507-2183
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational look at how PRX S cosmetic treatment changes skin appearance in adults with acne-prone skin
This pilot, single-group study tests whether a five-session PRX S treatment plan can change visible skin features in adults with acne-prone skin.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.